NVO Novo Nordisk A/S
DCF Model
Discounted cash flow valuation with 5-year FCF projections, WACC, terminal value, and sensitivity analysis.
Implied Price
$61.5
Current
$40.46
WACC
9.2%
Terminal Growth
2.5%
Fuente: Yahoo Finance, SEC EDGAR, Damodaran, Company Filings